In a study of pancreatic cancer, administration of OP in conjunction with aspirin has been proposed as a potential strategy to enhance the efficacy of gemcitabine, the standard chemotherapeutic agent for human pancreatic cancer, by reducing proliferation, metabolic activity, migration, and clonogenic formation on pancreatic cancer cells via targeting Neu-1 (25). This evidence concerns the gene NEU1 and familial pancreatic carcinoma.